Department of Surgery, Liver-Biliary and Pancreatic Unit, Biomedical Research Institute INCLIVA, Hospital Clinico University of Valencia, Spain.
CIBERONC Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Spain.
Cancer Treat Rev. 2018 Jul;68:124-135. doi: 10.1016/j.ctrv.2018.06.006. Epub 2018 Jun 13.
Pancreatic cancer is a dismal disease with an increasing incidence. Despite the majority of patients are not candidates for curative surgery, a subgroup of patients classified as borderline resectable pancreatic cancer can be selected in whom a sequential strategy of neoadjuvant therapy followed by surgery can provide better outcomes. Multidisciplinary approach and surgical pancreatic expertise are essential for successfully treating these patients. However, the lack of consensual definitions and therapies make the results of studies very difficult to interpret and hard to be implemented in some settings. In this article, we review the challenges of borderline resectable pancreatic cancer, the complexity of its management and controversies and point out where further research and international cooperation for a consensus strategy is urgently needed.
胰腺癌发病率不断上升，是一种预后极差的疾病。尽管大多数患者不适宜进行根治性手术，但有一部分被归类为边界可切除胰腺癌的患者，可以选择接受新辅助治疗序贯手术的治疗策略，从而获得更好的结果。多学科方法和外科胰腺专业知识对于成功治疗这些患者至关重要。然而，由于缺乏共识定义和治疗方法，使得研究结果非常难以解释，并且在某些情况下难以实施。本文回顾了边界可切除胰腺癌的挑战，以及其管理的复杂性和争议，并指出需要进一步开展研究和国际合作以制定共识策略。
